Clinicopathological data of the BC patients showed that both NTRK1 and NTRK2 were significantly upregulated in estrogen receptor-positive (ER+) patients, respectively (P-value: .0132 and <.0001). The gene discussed is NTRK2; the disease is breast cancer.